Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Treatment-Resistant Depression (P-TRD)
NCT04433858Phase 2Active, not recruiting
- Sponsor
- Sheppard Pratt
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Sheppard Pratt. Started Mar 2021; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04433858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433858.